MABVAX THERAPEUTICS HLDGS INC
MBVX
MBVX was delisted on the 10th of July, 2018.
15 hedge funds and large institutions have $2.29M invested in MABVAX THERAPEUTICS HLDGS INC in 2017 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
33% more capital invested
Capital invested by funds: $1.72M → $2.29M (+$566K)
0% more funds holding
Funds holding: 15 → 15 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$415K |
| 2 |
VF
Virtu Financial
New York
|
+$73.1K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$1.74K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$20K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$9.64K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Cambridge Investment Research Advisors
Fairfield,
Iowa
| $2.14M | +$415K | +187,834 | +23% |
|
|
VF
2
Virtu Financial
New York
| $69K | +$73.1K | +33,038 | New |
|
|
BCM
3
Biomark Capital Management
Greenwich,
Connecticut
| $19K | – | – | – |
|
4
Bank of America
Charlotte,
North Carolina
| $13K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $12K | -$9.64K | -4,359 | -43% |
|
|
BW
6
Bison Wealth
Atlanta,
Georgia
| $11K | – | – | – |
|
|
TSS
7
Two Sigma Securities
New York
| $9K | +$1.74K | +785 | +23% |
|
|
BJL
8
Brighton Jones LLC
Seattle,
Washington
| $7K | – | – | – |
|
|
DRD
9
Dennis R. Delaney
| $7K | – | – | – |
|
|
BCI
10
Brinker Capital Investments
Berwyn,
Pennsylvania
| $1K | – | – | – |
|
|
11
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$20K | -10,266 | Closed |
|
|
CA
12
Centerpoint Advisors
Needham,
Massachusetts
| – | +$449 | +203 | New |
|
MBVX Hedge Fund Activity: Q4 2017 in Review
15 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in MABVAX THERAPEUTICS HLDGS INC (MBVX) for Q4 2017, worth a combined $2.29M — up 33% from $1.72M a quarter earlier.
Fund positioning in MBVX was balanced in Q4 2017: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was Cambridge Investment Research Advisors, adding an estimated $415K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $20K sold.
- 15 institutional investors held MABVAX THERAPEUTICS HLDGS INC (MBVX) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $2.29M of MABVAX THERAPEUTICS HLDGS INC stock for Q4 2017, up 33% quarter-over-quarter.
- 2 funds opened new MABVAX THERAPEUTICS HLDGS INC positions in Q4 2017 and 2 closed out, a net change of 0 holders.
- The largest MABVAX THERAPEUTICS HLDGS INC buyer in Q4 2017 was Cambridge Investment Research Advisors, an estimated $415K added.
- The largest MABVAX THERAPEUTICS HLDGS INC seller in Q4 2017 was Susquehanna International Group, an estimated $20K sold.
Based on aggregated 13F filings for Q4 2017.